Eli Lilly defeats billion-dollar claim over trade secrets
US pharmaceutical group Eli Lilly & Company has defeated a US$1.8 billion claim by a French biotech company that alleged it had misused trade secrets and confidential information.
To read more
Subscribe to Global Arbitration Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Arbitration Review experts.